Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Industry attention remains focused on pipeline acquisitions and licensing as large pharmaceutical companies seek exposure to obesity and metabolic health assets
Crucially, there was reportedly no pharmacovigilance system in place to monitor or respond to adverse drug reactions, despite SAHPRA noting "reports of adverse events, including hospitalisations, linked to the use of these products." All GIP/GLP-1 injectable products found on the site were seized, and iDexis was instructed to initiate a full recall of affected products distributed through healthcare providers, pharmacies, and other channels
Related Blog Posts Call Us Today
Conversely, for women with polycystic ovary syndrome (PCOS) or obesity-related menstrual irregularities, weight loss can actually restore ovulatory cycles and improve period regularity
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
